New hope for ovarian cancer: targeted drug combo takes on resistant tumors
NCT ID NCT07504588
First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times
Summary
This phase II trial compares a new two-drug combination (sacituzumab govitecan plus bevacizumab) against standard chemotherapy (carboplatin, liposomal doxorubicin, and bevacizumab) in 87 women with platinum-sensitive ovarian cancer that has progressed after PARP inhibitor maintenance. The new combo uses a targeted antibody to deliver chemotherapy directly to cancer cells, while bevacizumab blocks blood vessel growth. The goal is to see if this approach can delay cancer progression better than current standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacituzumab govitecan and bevacizumab
- What this could lead to
- If it works, this could offer a new treatment option for women with ovarian cancer that has returned after initial therapy and PARP inhibitor maintenance.
- What could go wrong
- This is a small, early-phase trial (87 participants) and may not show a clear benefit over standard care. Side effects from the drugs can be serious, including low blood counts, fatigue, and bleeding risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLATINUM-SENSITIVE FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.